Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Midostaurin approved for FLT3-mutated AML.

Literature DB >> 28546144

Midostaurin approved for FLT3-mutated AML.

Abstract

Midostaurin was recently approved by the US Food and Drug Administration for the treatment of FLT3-mutant acute myeloid leukemia (AML). This is the first drug to receive regulatory approval for AML in the United States since the year 2000. Midostaurin is a small-molecule kinase inhibitor with activity against the receptor tyrosine kinase FLT3, and its approval will hopefully mark the beginning of an era of targeted agents for the treatment of molecularly defined subtypes of AML.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2017 PMID： 28546144 DOI： 10.1182/blood-2017-05-782292

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

Keyword Cloud
Cited

74 in total

1. Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation.

Authors: Su-Fern Tan; Wendy Dunton; Xin Liu; Todd E Fox; Samy A F Morad; Dhimant Desai; Kenichiro Doi; Mark R Conaway; Shantu Amin; David F Claxton; Hong-Gang Wang; Mark Kester; Myles C Cabot; David J Feith; Thomas P Loughran
Journal: J Lipid Res Date: 2019-04-08 Impact factor: 5.922

Review 2. Cytotoxic therapy in acute myeloid leukemia: not quite dead yet.

Authors: Laura C Michaelis
Journal: Hematology Am Soc Hematol Educ Program Date: 2018-11-30

Review 3. Using genomics to define pediatric blood cancers and inform practice.

Authors: Rachel E Rau; Mignon L Loh
Journal: Hematology Am Soc Hematol Educ Program Date: 2018-11-30

4. An oncoinformatics study to predict the inhibitory potential of recent FDA-approved anti-cancer drugs against human Polo-like kinase 1 enzyme: a step towards dual-target cancer medication.

Authors: Syed Mohd Danish Rizvi; Abdulaziz Arif A Alshammari; Waleed Abdullah Almawkaa; Abo Bakr F Ahmed; Ahmed Katamesh; Ahmed Alafnan; Tariq J Almutairi; Rakan F Alshammari
Journal: 3 Biotech Date: 2019-02-09 Impact factor: 2.406

Midostaurin approved for FLT3-mutated AML.

1. Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation.

Review 2. Cytotoxic therapy in acute myeloid leukemia: not quite dead yet.

Review 3. Using genomics to define pediatric blood cancers and inform practice.

4. An oncoinformatics study to predict the inhibitory potential of recent FDA-approved anti-cancer drugs against human Polo-like kinase 1 enzyme: a step towards dual-target cancer medication.

Review 5. Advances of small molecule targeting of kinases.

6. Azacytidine in Newly Diagnosed FLT3-ITD-Positive Acute Myeloid Leukemia Presenting with Pneumonia: A Case Series.

Review 7. The genomics of acute myeloid leukemia in children.

Review 8. The role of targeted therapy in the management of patients with AML.

Review 9. Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy.

Review 10. The evidence framework for precision cancer medicine.